People at intermediate risk of cardiovascular disease who have high levels of high sensitivity C-reactive protein, a blood marker for inflammation, could benefit from cholesterol-lowering therapy even if their cholesterol is already at desirable levels. Data indicates that people with only a 5 percent to 20 percent risk of having heart disease in the next 10 years, but who have high levels of hsCRP could reduce the risk of heart attack and stroke by more than 40 percent.